The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer
Top Cited Papers
Open Access
- 1 April 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (4) , 579-584
- https://doi.org/10.1093/annonc/mdi122
Abstract
Background: We examined the clinical relevance of skeletal-related events (SREs) for health state preferences, pain and health-related quality of life in patients with advanced prostate cancer and a history of bone metastases. Patients and methods: Data were from a clinical trial of zoledronic acid versus placebo in the treatment of SREs associated with advanced prostate cancer metastatic to bone. Patients (n=248) were included if they experienced an SRE during the study. Outcome measures were assessed at fixed intervals. We used mixed-effects models to estimate changes in outcomes after each patient's first SRE. Results: There were clinically meaningful and statistically significant declines in physical well-being after: radiation and pathologic fractures; functional well-being after radiation; and emotional well-being after radiation and pathologic fractures. There also were meaningful and significant declines in preference and utility scores after radiation and fracture. Pain intensity declined after radiation, but not after other SREs; no other pain measure changed substantively. Conclusions: SREs have important and significant effects on measures of health-related quality of life in men with prostate cancer. Treatments that prevent SREs may not demonstrate corresponding effects on outcomes if the effects of SREs occur between scheduled outcome assessments. Implications for trial design are discussed.Keywords
This publication has 17 references indexed in Scilit:
- Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI Journal of the National Cancer Institute, 2003
- Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.JNCI Journal of the National Cancer Institute, 2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI Journal of the National Cancer Institute, 2002
- Strategies for Management of Prostate Cancer-Related Bone PainDrugs & Aging, 2001
- INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINEJournal of Urology, 2000
- The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinomaCancer, 2000
- Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrumentUrology, 1997
- Quality-of-Life Outcomes in Men Treated for Localized Prostate CancerJAMA, 1995
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.Journal of Clinical Oncology, 1993
- Quality of Life of Patients with Advanced and Metastatic Prostatic CarcinomaEuropean Urology, 1993